Year in Review: Chronic Lymphocytic Leukemia - MedPage Today 12/10/2024
Other CLL research reported at ASH included early but promising data on single-agent epcoritamab (Epkinly) in heavily pretreated patients and the confirmatory trial of pirtobrutinib in patients who failed on prior BTK inhibition.
Other CLL research reported at ASH included early but promising data on single-agent epcoritamab (Epkinly) in heavily pretreated patients and the confirmatory trial of pirtobrutinib in patients who failed on prior BTK inhibition.